Back to results
US 2025/0061966 A1Published application
Methods and systems for assessing immune cell receptors and antigens
Assignee3T Biosciences, Inc.
InventorsMarvin Gee, Norman Goodacre, Eric Luxenberg, Leah Sibener
Life of this patent
Estimating the term…
Abstract
Described herein are methods and systems used to provide an exhaustive cross-reactivity profile for a TCR.
Claims25
A method of profiling a TCR or TCRm, the method comprising:
- (a) conducting one or more analyses to obtain a plurality of peptide binding predictions that are representative of peptide-HLA targets that a TCR binds;
- (b) conducting one or more analyses using the peptide binding predictions to obtain a plurality of peptide activation predictions that are representative of target peptides identified from step (a) that are predicted to activate the TCR;
- and
- (c) conducting one or more analyses using the peptide binding predictions and the peptide activation predictions to obtain a cross-reactivity profile of the TCR with respect to the target peptides identified from step (b) to thereby obtain a profile of the TCR.
1 more element
A method for treating a subject having a cancer that comprises cancer cells that display a target peptide, the method comprising:
- providing to the subject a therapeutic TCR that binds the target peptide to thereby treat the subject, wherein the therapeutic TCR was identified by a process comprising:
- (a) conducting one or more analyses to obtain a plurality of peptide binding predictions that are representative of the target peptide to which the TCR binds;
- (b) conducting one or more analyses using the peptide binding predictions to obtain a plurality of peptide activation predictions that are representative of target peptides identified from step (a) that are predicted to activate the TCR;
- (c) conducting one or more analyses using the peptide binding predictions and the peptide activation predictions to obtain a cross-reactivity profile of the TCR with respect to the target peptides identified from step (b) to thereby obtain a profile of the TCR;
- and
- (d) identifying the therapeutic TCR using the cross-reactivity profile of the TCR with respect.
3 more elements
A method for preparing a composition comprising a TCR useful for treating cancer in a subject, the method comprising:
- (a) obtaining tumor tissue from a subject and extracting tumor infiltrating lymphocytes from the tumor tissue;
- (b) conducting one or more analyses to obtain a plurality of peptide binding predictions that are representative of peptide-HLA targets in the tumor tissue that bind to a TCR of an extracted tumor infiltrating lymphocyte;
- (c) conducting one or more analyses using the peptide binding predictions to obtain a plurality of peptide activation predictions that are representative of target peptides identified from step (a) that are predicted to activate the TCR;
- (d) conducting one or more analyses using the peptide binding predictions and the peptide activation predictions to obtain a cross-reactivity profile of the TCR with respect to the target peptides identified from step (b) to thereby obtain a profile of the TCR;
- and
- (e) causing engineered immune cells to express the TCR.
3 more elements
Dependencies are inferred from the claim text.